Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUCMSC Secretome in Drug Resistant Epilepsy
NCT06638970Phase 1Not yet recruiting
- Sponsor
- Baermed
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of human umbilical cord mesenchymal stem cell secretome in epilepsy (2 arms), sponsored by Baermed. Primary endpoints: Changes frequency and duration of the seizures at 8 months and Changes in EEG and qEEG results at 8 months. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell secretome
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT06638970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06638970.